Oroxylum indicum for Health & Longevity

Evidence Review created on 07/30/2026 using AI4L / Opus 4.8

Also known as: Sabroxy, Indian Trumpet Tree, Broken Bones Plant, Midnight Horror Tree, Sonapatha, Shyonaka, Bignonia indica

Motivation

Oroxylum indicum is a tall flowering tree native to India and Southeast Asia, easily recognized by its long, sword-shaped seed pods that hang in the dark like blades — the source of nicknames such as “Broken Bones” and “Midnight Horror.” Its bark, seeds, and roots have been used for centuries in traditional Indian medicine, and the plant is rich in a family of natural plant pigments called flavonoids, most notably baicalein, oroxylin A, and chrysin. In recent years a standardized bark extract (sold as Sabroxy) has been marketed as a brain-support supplement, which is what draws the attention of health- and longevity-minded readers.

The renewed interest comes from laboratory findings that these flavonoids can calm inflammation, mop up cell-damaging molecules, and nudge signals in the brain linked to learning and memory. A single controlled human study reported modest memory improvements in older adults, while most other evidence still comes from cell and animal experiments.

This review examines what is actually known about Oroxylum indicum — its proposed benefits for memory, blood sugar, and inflammation, its possible risks and drug interactions, how it has been used, and how strong the underlying evidence really is.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Oroxylum indicum - Grokipedia

Grokipedia hosts a dedicated encyclopedia entry on the species covering its botany, phytochemistry, and traditional medicinal uses, providing a broad reference-level orientation to the plant.

Examine

Oroxylum indicum - Examine

Examine maintains an evidence-graded page summarizing the human and preclinical research on Oroxylum indicum, including its studied roles in cognition and blood-sugar regulation, with independent interpretation of study quality.

ConsumerLab

No ConsumerLab article or product-testing review dedicated to Oroxylum indicum (or the Sabroxy extract) was found.

Systematic Reviews

This section summarizes the systematic reviews that pool the available Oroxylum indicum research, which to date remains dominated by laboratory and animal studies.

A Systematic Review of Evidence-Based Health Benefits of Oroxylum indicum and Its Functional Food Potential - Nguyen et al., 2025

The most comprehensive synthesis to date, screening 185 articles from 2010–2025 and confirming consistent flavonoid content (baicalein, baicalin, oroxylin A, chrysin) with antioxidant, cardiovascular, neurological, and antidiabetic signals; it explicitly flags the near-absence of human trials and long-term safety data as the key gap.
The Biological Activities and Therapeutic Potentials of Baicalein Extracted from Oroxylum indicum: A Systematic Review - Nik Salleh et al., 2020

A systematic review of 20 qualifying studies on baicalein from the plant, documenting anticancer, antibacterial, blood-sugar-lowering, neurogenic, cardioprotective, and anti-inflammatory effects while noting that essentially all evidence is preclinical and human confirmation is lacking.
Ethnopharmacologically important highly subsidized Indian medicinal plants: Systematic review on their traditional uses, phytochemistry, pharmacology, quality control, conservation status and future prospective - Anmol et al., 2024

A systematic review of high-priority Indian medicinal plants that includes Oroxylum indicum, situating its traditional uses and phytochemistry alongside conservation concerns — relevant because over-harvesting has made sustainable sourcing a genuine issue for this species.

Mechanism of Action

The health effects attributed to Oroxylum indicum are driven mainly by three flavonoids concentrated in the bark and seeds: baicalein, oroxylin A, and chrysin. Their actions overlap, which is why the whole extract is described as “multi-target.”

Oroxylin A (the cognition-linked flavonoid): In laboratory studies it blocks the reuptake of dopamine (a reward-and-focus brain chemical), acts as a mild blocker at the GABA-A receptor (GABA, gamma-aminobutyric acid, is the brain’s main calming signal; blunting it can promote alertness), and raises levels of BDNF (brain-derived neurotrophic factor, a protein that supports the growth and survival of nerve cells). It also inhibits MAO-B (monoamine oxidase B, an enzyme that breaks down dopamine), which would tend to increase dopamine availability.
Baicalein (the antioxidant/anti-inflammatory flavonoid): It is a strong scavenger of cell-damaging molecules, chelates (binds) iron, and inhibits 12/15-lipoxygenase (an enzyme that produces inflammatory messengers). It dampens NF-κB (nuclear factor kappa B, a master “on-switch” for inflammation) and activates Nrf2 (a protein that turns on the cell’s own antioxidant defenses). It also inhibits α-glucosidase (an intestinal enzyme that breaks starch into sugar), which underlies its blood-sugar effects.
Chrysin (the hormone- and mood-linked flavonoid): It inhibits aromatase (the enzyme that converts testosterone into estrogen) and has calming activity at the benzodiazepine site of the GABA-A receptor in animal models.
Competing mechanistic views: One view holds that the extract’s cognitive effect is mainly dopaminergic and wake-promoting (an oroxylin A effect); a competing view attributes it to reduced brain inflammation and higher BDNF (a baicalein effect). A significant counter-argument applies to all of these: baicalein and its relatives are poorly absorbed and rapidly converted in the gut and liver, so effects seen at high concentrations in a dish may not occur at realistic oral doses.
Pharmacological properties: Baicalein is absorbed quickly but then extensively converted by UGT enzymes (UDP-glucuronosyltransferases, which attach sugar groups to clear compounds) into baicalin, giving it a short half-life of only a few hours and prominent recycling between gut and liver. The flavonoids distribute widely, cross into the brain to a limited degree, and in laboratory tests can inhibit several CYP enzymes (cytochrome P450, the liver’s main drug-metabolizing enzymes, including CYP3A4) and UGT enzymes — the basis for its potential drug interactions. There is no single receptor target; the extract works through broad, low-potency “polypharmacology.”

Historical Context & Evolution

Original use: Oroxylum indicum has been used for well over two thousand years in Ayurveda (the traditional medicine system of the Indian subcontinent) and in neighboring Southeast Asian traditions. Its root bark, called Shyonaka or Sonapatha, is one of the ten roots of the classic Ayurvedic formula Dashamoola, and it was applied for inflammation, joint and rheumatic complaints, respiratory and digestive ailments, fever, and diabetes. The young pods are still eaten as a bitter vegetable in parts of Southeast Asia.
Why it drew interest for health optimization: Modern chemical analysis showed the bark is unusually rich in baicalein and related flavonoids — the same class of compounds prized in the Chinese medicinal herb Scutellaria baicalensis. As these flavonoids were shown in the lab to have antioxidant, anti-inflammatory, and nerve-supporting actions, interest shifted from the whole traditional preparation toward standardized extracts. Around 2019–2020 an extract standardized to oroxylin A was commercialized as a nootropic (a supplement marketed to support thinking and memory), and the first human cognition trial followed in 2021.
What the early findings actually showed: The traditional record and early pharmacology consistently pointed to anti-inflammatory and antioxidant activity, and isolated flavonoids showed inhibition of enzymes involved in cancer growth and microbial infection — findings that were reported as genuine laboratory results rather than proven clinical cures.
Evolution of the evidence: The field has moved from ethnobotanical description toward mechanism and, very recently, toward small human trials. The current picture is not settled: enthusiasm rests largely on preclinical data and one modest clinical study, and newer trials (including in metabolic health) are underway that could strengthen or weaken the case.

Expected Benefits

Benefits are framed for a proactive, health-optimizing adult. Note that the great majority of evidence is preclinical (cell and animal studies); only cognition has been tested in a controlled human trial, which was funded by the extract’s manufacturer (Sami-Sabinsa) — a conflict of interest that recurs across much of the supporting literature.

Medium 🟩 🟩

Memory & Cognitive Function in Older Adults

The most direct human evidence is a 12-week randomized, double-blind, placebo-controlled trial in 82 older adults with self-reported memory complaints, using 500 mg of standardized extract twice daily. Compared with placebo, the extract produced greater improvements in episodic memory (recall of specific events), immediate word recall, and numeric working memory, plus faster visuospatial learning. Proposed mechanisms include higher dopamine availability and raised BDNF. Important caveats: this is a single, manufacturer-funded study, several cognitive measures showed no benefit, and blood BDNF rose equally in both groups.

Magnitude: Statistically significant gains on episodic-memory and working-memory tasks over 12 weeks in one 82-person trial; individual effect sizes were small-to-moderate, and the overall cognitive screening score did not differ from placebo.

Low 🟩

Antioxidant & Anti-Inflammatory Activity

Across many cell and animal studies, the plant’s flavonoids reduce oxidative stress and suppress inflammatory signaling (notably NF-κB and lipoxygenase pathways), and activate the Nrf2 antioxidant defense system. This is the most consistently reproduced effect and plausibly underlies several of the other proposed benefits. Human confirmation at realistic oral doses is lacking, and the poor absorption of flavonoids tempers expectations.

Magnitude: Not quantified in available studies.

Blood Sugar Regulation

Extracts and isolated baicalein inhibit α-glucosidase and improve markers of glucose handling and insulin sensitivity in laboratory and rodent models, supporting the plant’s traditional use in diabetes. A dedicated human trial in adults with insulin resistance is currently recruiting, so this benefit is mechanistically promising but not yet demonstrated clinically.

Magnitude: Not quantified in available studies.

Liver Protection

In animal models, root-bark extract reduced chemical- and drug-induced liver injury and helped restore the body’s antioxidant balance, and a mouse study found no liver toxicity at a physiologically relevant dose. This suggests a protective rather than harmful liver profile, though all supporting data are preclinical.

Magnitude: Not quantified in available studies.

Speculative 🟨

Cardiometabolic & Lipid Effects

In cell and rodent studies, oroxin A and related compounds reduced fat accumulation, improved lipid metabolism (partly by inhibiting SREBP proteins that drive cholesterol and fat production), and blunted fat-cell formation via PPARγ (a receptor controlling fat storage). The basis is mechanistic and animal-only; no human lipid or weight outcomes have been reported.

Anticancer Potential

Numerous in-vitro and in-silico studies report that baicalein and whole extracts slow the growth of cancer cell lines and interfere with tumor-promoting pathways. This is early-stage laboratory work with no human evidence, and it should not be read as any indication for cancer prevention or treatment.

Mood & Antidepressant Effects

Seed and bark extracts produced antidepressant- and anxiety-reducing effects in mouse stress models, consistent with the GABA-calming activity of chrysin and the dopamine effects of oroxylin A. The evidence is limited to animal behavior tests.

Antimicrobial Activity

Extracts show activity against various bacteria, including some antibiotic-resistant strains, in laboratory dishes. This is purely in-vitro and does not establish any clinical antimicrobial use.

Benefit-Modifying Factors

Genetic variation in flavonoid clearance: Differences in UGT and CYP enzyme activity affect how quickly baicalein is converted and cleared, which may make some people “fast metabolizers” who derive less exposure from a standard dose. This is inferred from pharmacology rather than shown directly.
Baseline inflammation and oxidative burden: People starting with higher inflammation or oxidative stress (for example, from metabolic dysfunction) are the most plausible responders to an antioxidant/anti-inflammatory herb; those already at a healthy baseline may see little.
Baseline cognitive status: The one positive human trial enrolled older adults with self-reported memory complaints; benefits in younger, cognitively healthy adults are unproven and may be smaller.
Sex-based differences: Because chrysin can inhibit aromatase (the estrogen-making enzyme), hormonal responses could theoretically differ between men and women, but no sex-stratified human data exist.
Age: The evidence for cognitive benefit comes specifically from older adults, so this may be more relevant toward the older end of the target range; metabolic effects are untested by age.

Potential Risks & Side Effects

Risks are framed for a proactive adult self-supplementing. Human safety data are limited to one 12-week trial; most concerns below are extrapolated from the pharmacology of the flavonoids.

Medium 🟥 🟥

Gastrointestinal Discomfort

In the only controlled human trial, the extract was well tolerated overall but caused a higher rate of mild digestive complaints than placebo. The likely mechanism is direct irritation from the bitter flavonoid-rich extract. It appears mild, reversible on stopping, and reducible by taking the extract with food.

Magnitude: Higher rate of mild digestive complaints than placebo at 1,000 mg/day over 12 weeks; no serious gastrointestinal events reported.

Headache

The same trial reported an increased tendency toward mild headaches versus placebo. The mechanism is unclear but may relate to the extract’s dopamine- and MAO-related activity. Reported cases were mild and self-limiting.

Magnitude: Mild, transient headaches somewhat more common than placebo at 1,000 mg/day; no severe or persistent cases reported.

Low 🟥

Increased Bleeding Tendency

Baicalein inhibits platelet aggregation and lipoxygenase pathways in laboratory studies, which could, in principle, add to the effect of blood thinners and raise bleeding risk. No bleeding events were reported in the human trial, but the antiplatelet signal is consistent enough to warrant caution around surgery or anticoagulant use.

Magnitude: Not quantified in available studies; antiplatelet effect demonstrated in vitro and in animal models only.

Drug-Metabolism Interactions

In laboratory tests, the plant’s flavonoids inhibit several CYP and UGT enzymes that clear medications, meaning they could raise blood levels of drugs processed by those enzymes. The clinical size of this effect at realistic supplement doses is unknown but plausibly meaningful for narrow-margin drugs.

Magnitude: Not quantified in available studies; enzyme inhibition shown in vitro without human interaction studies.

Speculative 🟨

Hormonal Effects (Estrogen Lowering)

Chrysin inhibits aromatase in laboratory models, raising a theoretical possibility of lowered estrogen, which could matter for hormone-sensitive conditions. In practice, oral chrysin is very poorly absorbed and human hormonal effects have not been demonstrated.

Reduced Iron Absorption

Baicalein binds iron, so taken with meals it could modestly reduce dietary iron uptake — a theoretical concern mainly for people prone to iron deficiency. No human data quantify this.

Additive Sedation or Overstimulation

The flavonoids act on GABA and dopamine systems, so combining the extract with sedatives or stimulants could theoretically add unpredictably to those effects. This is a mechanistic caution only.

Unknown Long-Term Safety

No human study has run beyond 12 weeks, and the safety of daily use over months to years — the timeframe a longevity-oriented user would consider — is simply unstudied. Endangered-plant sourcing also raises the risk of adulteration or contamination in unregulated products.

Risk-Modifying Factors

Genetic variation in drug-metabolizing enzymes: People with lower CYP or UGT activity may accumulate higher flavonoid or co-administered-drug levels, amplifying interaction risk. This is inferred from pharmacology.
Baseline platelet function and clotting status: Those with low platelets, a bleeding disorder, or on anticoagulants sit at the high-risk end of the theoretical bleeding concern.
Sex-based differences: Aromatase inhibition by chrysin could, in theory, have different hormonal consequences in women (particularly post-menopausal) versus men; this is unquantified.
Pre-existing conditions: Diabetes (additive blood-sugar lowering), hormone-sensitive conditions, iron-deficiency states, and liver disease could each shift the risk-benefit balance.
Age: Older adults — the group most likely to use it for cognition — are also more likely to be on interacting medications and to have reduced drug clearance, raising interaction risk toward the older end of the range.

Key Interactions & Contraindications

Anticoagulant and antiplatelet drugs (warfarin, apixaban, clopidogrel, aspirin): Caution — additive bleeding risk from baicalein’s antiplatelet activity. If combined, monitor for bruising or bleeding and separate from any procedure.
Antidiabetic drugs (metformin, sulfonylureas such as glipizide, insulin): Caution — potential additive blood-sugar lowering leading to hypoglycemia; monitor glucose more closely if combined.
Narrow-therapeutic-index drugs metabolized by CYP3A4/CYP enzymes (e.g., certain statins, immunosuppressants, some benzodiazepines): Caution — flavonoid enzyme inhibition could raise drug levels; consider timing separation and clinical monitoring.
Sedatives and central-nervous-system depressants (benzodiazepines, alcohol, sleep aids): Caution — theoretical additive effect through GABA activity.
Over-the-counter medications: NSAIDs (non-steroidal anti-inflammatory painkillers such as ibuprofen) and aspirin (additive bleeding risk); sedating antihistamines (additive drowsiness).
Supplement interactions: Other blood-thinning supplements (fish oil, ginkgo, garlic, high-dose vitamin E) may add to bleeding risk; other glucose-lowering supplements (berberine, cinnamon) may add to hypoglycemia risk.
Additive-effect supplements: Other dopaminergic or MAO-B-affecting nootropics may compound stimulation, sleep disruption, or interaction potential.
Iron supplements: Baicalein chelates iron — separate dosing by at least 2 hours to avoid reduced absorption of either.
Populations who should avoid it: Pregnant or breastfeeding women (no safety data); people with bleeding disorders or scheduled surgery (stop at least 2 weeks prior); those on warfarin or other anticoagulants unless supervised; people with hormone-sensitive conditions (theoretical aromatase effect); and children (untested).

Risk Mitigation Strategies

Start low and take with food: Begin at the low end (e.g., 100–250 mg of standardized extract once daily) and take with a meal to minimize the mild gastrointestinal discomfort and headache seen in the human trial.
Dose earlier in the day: Because the extract’s dopamine-related activity can be mildly stimulating, take it in the morning or early afternoon to reduce the risk of sleep disruption.
Pause before surgery or dental procedures: Stop the supplement at least 2 weeks before any procedure to mitigate the theoretical antiplatelet/bleeding risk.
Monitor if combining with glucose- or clot-affecting agents: If used alongside antidiabetic or anticoagulant drugs, check blood sugar or watch for bleeding signs, respectively, to catch additive effects early.
Separate from iron and time-sensitive medications: Take at least 2 hours apart from iron supplements and from narrow-margin medications to limit chelation and enzyme-interaction effects.
Choose a third-party-tested, standardized product: Use a branded, heavy-metal-tested extract to mitigate the contamination and adulteration risk that comes with an over-harvested wild plant.

Therapeutic Protocol

Standard protocol: The most evidence-based regimen mirrors the human trial — a bark extract standardized to oroxylin A, taken as 500 mg twice daily (1,000 mg/day). Consumer nootropic use is often more conservative, at 100–300 mg once or twice daily.
Competing approaches: A “clinical-dose” approach follows the trial’s 1,000 mg/day; a “low-dose stacking” approach uses 100–300 mg as one component of a broader nootropic blend. Neither has been shown superior, and this review does not favor one; the higher dose has the only direct human support, while the lower dose reflects real-world tolerability practice.
Who popularized each: The 1,000 mg/day regimen derives from the Sami-Sabinsa Sabroxy trial (Lopresti and colleagues); the lower stacking doses were popularized by nootropic retailers such as Nootropics Depot.
Best time of day: Morning or early afternoon is preferred, given the mildly stimulating dopamine-related activity; late-day dosing may interfere with sleep.
Half-life: The active baicalein is short-lived (a few hours) because it is rapidly converted to baicalin, which supports split (twice-daily) dosing rather than a single dose.
Single vs. split dosing: Because of the short half-life, the trial and most protocols split the dose morning and midday to maintain steadier exposure.
Genetic considerations: Variation in UGT/CYP enzyme activity may influence exposure and interaction risk, but no pharmacogenetic testing is established for this supplement.
Sex-based considerations: No sex-specific dosing has been studied; the theoretical aromatase effect of chrysin is the only sex-relevant signal and is unquantified.
Age-related considerations: Older adults (the studied group) may be more sensitive to interactions and reduced clearance, favoring the lower starting dose.
Baseline biomarkers: Higher baseline inflammation, glucose, or memory complaints may predict more noticeable effects; there is no validated biomarker to guide dosing.
Pre-existing conditions: Diabetes, bleeding risk, and hormone-sensitive conditions should shape whether and how the protocol is used, as detailed in the interactions section.

Discontinuation & Cycling

Lifelong vs. short-term: It is used as an optional, ongoing supplement rather than a lifelong medication; there is no evidence requiring indefinite use, and no established benefit beyond the 12-week studied window.
Withdrawal effects: No withdrawal syndrome has been reported; the extract does not appear to cause physical dependence and can be stopped without tapering.
Tapering: No taper is needed on current evidence; it can be discontinued abruptly.
Cycling: Some nootropic users cycle it (for example, several weeks on followed by a break, or 5 days on / 2 days off) on the theory that dopamine- and MAO-related effects could develop tolerance, but there is no clinical evidence that cycling maintains efficacy.
Practical framing: Because durable benefits are unproven, periodic breaks to reassess whether any subjective benefit persists are a reasonable, low-risk approach.

Sourcing and Quality

Standardization matters most: Look for a bark extract standardized to a stated oroxylin A content (commonly a minimum of 10%), such as the branded Sabroxy extract, rather than unstandardized raw bark powder whose flavonoid content is unpredictable.
Third-party testing: Prefer products with independent testing for heavy metals, pesticides, and identity, since wild-harvested bark can carry contaminants and the species is prone to substitution.
Sustainability and authenticity: Because Oroxylum indicum is over-harvested and considered threatened in parts of its range, sourcing from suppliers with cultivated or verified supply chains reduces both adulteration risk and conservation harm.
Reputable sources: The clinically studied material is the Sami-Sabinsa Sabroxy extract; retailers such as Nootropics Depot sell standardized Sabroxy-based products with published certificates of analysis.
Formulation: Capsules or tablets of the standardized extract are the practical form; some products add a black-pepper compound (piperine) intended to improve absorption of the poorly bioavailable flavonoids.

Practical Considerations

Time to effect: Cognitive benefits in the human trial were measured at 12 weeks; a realistic expectation is several weeks of daily use before any subjective change, not an acute effect.
Common pitfalls: Buying non-standardized bark powder, dosing late in the day and disrupting sleep, expecting a fast stimulant-like effect, and overlooking interactions with blood thinners or diabetes medications.
Regulatory status: In the United States and most markets it is sold as a dietary supplement, not an approved drug; it is not FDA-approved to diagnose, treat, or prevent any disease, and marketing claims outrun the clinical evidence.
Cost and accessibility: Standardized extracts are moderately priced and widely available online as nootropic supplements; cost and access are not major barriers.
Bitterness: The whole-plant material is notably bitter, which is why standardized encapsulated extracts, rather than teas or powders, dominate practical use.

Interaction with Foundational Habits

Sleep: Direction — potentially disruptive if mistimed. The dopamine-related, mildly stimulating activity of oroxylin A can interfere with sleep onset if taken late; dosing before mid-afternoon is the practical mitigation. Any calming GABA effects from chrysin appear not to offset this in practice.
Nutrition: Direction — potentiating (absorption) and mildly protective. Taking the extract with food reduces stomach upset, and some formulations pair it with piperine to improve the otherwise poor absorption of its flavonoids. Because baicalein binds iron, it is best separated from iron-rich meals or supplements.
Exercise: Direction — uncertain, possibly blunting at high antioxidant doses. There is no direct exercise data; by analogy to other high-dose antioxidants, heavy antioxidant loading could theoretically dampen some of the beneficial oxidative signaling that drives training adaptations, so timing away from workouts is a cautious option. This is speculative.
Stress management: Direction — potentially supportive. Animal models show antidepressant- and anxiety-reducing effects, consistent with chrysin’s calming GABA activity and oroxylin A’s dopamine effects, suggesting it may complement stress-reduction practices, though human mood data are absent.

Monitoring Protocol & Defining Success

Baseline testing is optional for a low-risk supplement but is sensible for anyone with diabetes, bleeding risk, or who intends long-term use; the goal is to catch additive metabolic or bleeding effects and to establish a reference for subjective cognitive tracking. Ongoing monitoring is light: for most users, re-check relevant labs at roughly 3 months and then every 6–12 months if use continues, and reassess subjective cognitive benefit at 8–12 weeks to decide whether to continue.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Fasting glucose	75–90 mg/dL	Detects additive blood-sugar lowering, especially if diabetic	Fast 8–12 h; pair with HbA1c (average blood sugar over ~3 months)
HbA1c	< 5.4%	Tracks longer-term glucose effect	No fasting needed; check at baseline and ~3–6 months
ALT / AST	ALT < 25 (men) / < 20 (women) U/L	Screens for any liver stress with long-term herbal use	ALT and AST are liver enzymes measured in blood; conventional labs flag only much higher values (~40 U/L); best drawn fasting
hs-CRP	< 1.0 mg/L	Gauges whether the anti-inflammatory effect is meaningful	hs-CRP is high-sensitivity C-reactive protein, a marker of inflammation; avoid testing during acute illness or injury
Ferritin / iron studies	Ferritin 50–150 ng/mL	Watches for reduced iron status given baicalein’s iron binding	Most relevant for menstruating women or those prone to deficiency
Platelet count / CBC	Within lab reference range	Baseline before combining with blood-affecting agents	CBC is a complete blood count; pair with clinical watch for easy bruising if on anticoagulants

Qualitative markers to track alongside labs:

Memory and recall in daily tasks (names, appointments, where items were placed)
Mental focus, motivation, and processing speed
Mood and stress resilience
Sleep quality (to catch any dosing-related disruption)
Energy levels through the day

Emerging Research

Research framed for a proactive reader tracking whether the case for Oroxylum indicum strengthens or weakens.

Metabolic + cognitive trial (strengthening test): An 8-week randomized, placebo-controlled trial (NCT07220694) is recruiting ~140 adults with both mild cognitive impairment and insulin resistance, testing 250 mg Sabroxy daily; the primary endpoint is change in insulin resistance (HOMA-IR, a blood-test index of insulin resistance), with cognition and BDNF as secondary measures. A positive result would extend the evidence beyond cognition into metabolic health.
Second cognition trial (replication test): A completed 12-week randomized, placebo-controlled study (NCT07189754) enrolled ~70 adults aged 60–85 with mild memory concerns, with primary endpoints of MoCA (Montreal Cognitive Assessment) score, computerized cognitive accuracy, and reaction time, plus blood BDNF. Its results will show whether the original memory finding replicates independently of the first trial’s design.
Brain-aging mechanisms (supporting direction): Animal work reported that Oroxylum indicum improved memory and boosted new nerve-cell formation in the hippocampus in a chemically induced aging model (Tanrangka et al., 2025), pointing to a plausible longevity-relevant mechanism that still requires human testing.
Alzheimer’s-targeted analysis (supporting direction): A recent review examined the plant’s root constituents against Alzheimer’s disease targets (Summat et al., 2025), mapping which flavonoids engage amyloid- and inflammation-related pathways and framing future drug-development questions.
Key open questions (could weaken the case): Whether the poorly absorbed flavonoids reach active levels in humans at realistic doses, whether benefits persist beyond 12 weeks, and whether independent (non-manufacturer) trials reproduce the cognitive signal remain the decisive unknowns.

Conclusion

Oroxylum indicum is a traditional Asian medicinal tree whose bark is rich in flavonoids — chiefly baicalein, oroxylin A, and chrysin — now sold as a standardized brain-support supplement. Its most direct human support is a single 12-week study in older adults with memory complaints, which found modest gains in memory and learning; this is the strongest signal, but it comes from one small trial funded by the extract’s maker, so it should be read with caution. Beyond that, a large body of cell and animal research points to antioxidant, anti-inflammatory, blood-sugar-lowering, and liver-protective effects, and to more preliminary possibilities for mood, heart, and even cancer-related pathways — but almost none of this has been confirmed in people, and the compounds are poorly absorbed.

On the risk side, the herb was generally well tolerated, with mainly mild stomach upset and headache; the more meaningful cautions are theoretical, involving added bleeding risk, blood-sugar lowering, and drug interactions, plus unknown long-term safety and sustainability concerns for an over-harvested plant. Overall, the evidence base is thin and leans heavily on laboratory work and manufacturer-linked studies. For a health-focused adult, it is a low-cost, low-acute-risk option with genuinely promising but still unproven benefits, best approached as an experiment to monitor rather than a settled tool.

Top - Benefits - Risks - Protocol

Oroxylum indicum for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

Medium 🟩 🟩

Memory & Cognitive Function in Older Adults

Low 🟩

Antioxidant & Anti-Inflammatory Activity

Blood Sugar Regulation

Liver Protection

Speculative 🟨

Cardiometabolic & Lipid Effects

Anticancer Potential

Mood & Antidepressant Effects

Antimicrobial Activity

Benefit-Modifying Factors

Potential Risks & Side Effects

Medium 🟥 🟥

Gastrointestinal Discomfort

Headache

Low 🟥

Increased Bleeding Tendency

Drug-Metabolism Interactions

Speculative 🟨

Hormonal Effects (Estrogen Lowering)

Reduced Iron Absorption

Additive Sedation or Overstimulation

Unknown Long-Term Safety

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion